Numerous clinical trials evaluate the therapeutic spectrum of BI-10773 (empagliflozin) across early- to late-phase studies, encompassing active, recruiting, completed, and terminated protocols supported by sponsors ranging from Boehringer Ingelheim to academic and government networks. Primary indications under investigation include type 1 and type 2 diabetes mellitus, heart failure with reduced ejection fraction, chronic kidney disease, and nephrotic syndrome. Additional research focuses on pediatric heart failure, post-transplant glycemic management in kidney transplant recipients, and healthy volunteers to evaluate safety, pharmacokinetics, and clinical utility.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07533747 | NOT_YET_RECRUITING | Coronary Microvascular Dysfunction (CMD) |
King's College London |
2026-05 | PHASE3 |
| NCT03424005 | RECRUITING | Metastatic Breast Cancer |
Hoffmann-La Roche |
2018-03-30 | PHASE1; PHASE2 |
| NCT06653738 | RECRUITING | Kidney Stone; Nephrolithiasis; Dietary Exposure |
Insel Gruppe AG, University Hospital Bern |
2026-07-02 | PHASE3 |
| NCT06992440 | RECRUITING | Pulmonary Arterial Hypertension |
Gustavo A Heresi, MD, MS |
2025-06-26 | PHASE2 |
| NCT06013865 | RECRUITING | Kidney Transplant; Chronic Kidney Disease |
VA Office of Research and Development |
2024-04-05 | PHASE4 |
| NCT07064473 | RECRUITING | Diabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases |
Boehringer Ingelheim |
2025-07-22 | PHASE3 |
| NCT07175051 | RECRUITING | Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0); Albuminuria |
University of Illinois at Chicago |
2026-04-08 | PHASE2 |
| NCT06642623 | RECRUITING | Diabetes Mellitus, Type 2; Cardiovascular Diseases; Kidney Diseases |
Yonsei University |
2024-01-22 | PHASE4 |
| NCT06625073 | RECRUITING | Heart Transplant; Cardiovascular Disease; Kidney Disease |
VA Office of Research and Development |
2026-01-20 | PHASE4 |
| NCT07635953 | NOT_YET_RECRUITING | Diabetes Mellitus |
Sun Yat-sen University |
2026-07-01 | PHASE3 |
| NCT07060417 | NOT_YET_RECRUITING | Non-diabetic Chronic Kidney Disease |
VA Office of Research and Development |
2026-10-01 | PHASE2 |
| NCT07775846 | NOT_YET_RECRUITING | Type 2 Diabetic Kidney Disease |
Huijie Zhang |
2026-09-01 | PHASE4 |
| NCT06935370 | RECRUITING | Heart Failure |
Boehringer Ingelheim |
2025-05-20 | PHASE3 |
| NCT07322237 | RECRUITING | Cirrhotic Cardiomyopathy; Empagliflozin; Cardiometabolic Risk Factors; Cirrhosis |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2026-04-01 | PHASE4 |
| NCT06507657 | RECRUITING | Hypertension; Cardiovascular Diseases |
University of Minnesota |
2024-12-12 | EARLY_PHASE1 |
| NCT06946628 | NOT_YET_RECRUITING | Diabetes Mellitus |
Sun Yat-sen University |
2025-06-01 | PHASE3 |
| NCT06642272 | RECRUITING | Diabetes Mellitus, Type 2; Heart Failure; Chronic Kidney Diseases |
Herlev and Gentofte Hospital |
2024-10-10 | PHASE4 |
| NCT06745063 | RECRUITING | Obesity; Vascular Health |
VA Office of Research and Development |
2025-05-30 | PHASE2 |
| NCT07228195 | RECRUITING | Partial Islet Function; TPIAT; Diabetes |
University of Minnesota |
2026-07-21 | PHASE4 |
| NCT07055282 | RECRUITING | Kidney Stones |
University of Chicago |
2025-11-20 | EARLY_PHASE1 |
| NCT06506422 | RECRUITING | Aging; Arterial Stiffness |
University of Missouri-Columbia |
2024-08-18 | PHASE2; PHASE3 |
| NCT04381936 | RECRUITING | Pneumonia |
University of Oxford |
2020-03-19 | PHASE3 |
| NCT07799441 | NOT_YET_RECRUITING | Blood Pressure; Endothelial Dysfunction |
Kanokwan Bunsawat |
2026-09 | PHASE4 |
| NCT06531824 | RECRUITING | Kidney Disease, Chronic |
Boehringer Ingelheim |
2024-08-30 | PHASE3 |
| NCT06424288 | RECRUITING | Heart Failure |
Boehringer Ingelheim |
2024-06-17 | PHASE3 |
| NCT07074418 | NOT_YET_RECRUITING | Chronic Kidney Diseases |
Centre Hospitalier Universitaire de Nice |
2026-09 | PHASE4 |
| NCT07756294 | NOT_YET_RECRUITING | Alzheimer Disease |
Wake Forest University Health Sciences |
2026-09 | PHASE2 |
| NCT06674109 | RECRUITING | Gout and Hyperuricemia |
Massachusetts General Hospital |
2026-07-01 | PHASE4 |
| NCT07304817 | RECRUITING | CKD; Cardiovascular Diseases; Heart Failure |
University Medical Center Groningen |
2026-05-12 | PHASE2 |
| NCT05271162 | ACTIVE_NOT_RECRUITING | Cardiotoxicity |
Maria Sklodowska-Curie National Research Institute of Oncology |
2023-09-30 | PHASE3 |
| NCT03867487 | NOT_YET_RECRUITING | Non-Alcoholic Fatty Liver Disease; NAFLD; Pediatric NAFLD |
Justin Ryder |
2027-05-01 | PHASE2 |
| NCT06355310 | RECRUITING | Non-Alcoholic Fatty Liver Disease |
Justin Ryder |
2025-04-10 | PHASE2 |
| NCT07771010 | RECRUITING | Diabetes Type 2 |
University Medical Centre Ljubljana |
2026-04-16 | PHASE4 |
| NCT06249932 | RECRUITING | Heart Failure with Reduced Ejection Fraction; End Stage Renal Disease on Dialysis |
National Taiwan University Hospital |
2024-03-13 | PHASE4 |
| NCT05147090 | ACTIVE_NOT_RECRUITING | Chronic Hepatitis b; NAFLD; Cirrhosis; Fibrosis, Liver; Empagliflozin; SGLT2 Inhibitors |
The University of Hong Kong |
2022-01-02 | PHASE4 |
| NCT06249945 | RECRUITING | Heart Failure With Preserved Ejection Fraction; End Stage Renal Disease on Dialysis |
National Taiwan University Hospital |
2024-03-05 | PHASE4 |
| NCT06110130 | RECRUITING | Chronic Kidney Diseases |
Washington D.C. Veterans Affairs Medical Center |
2024-02-02 | PHASE4 |
| NCT06955260 | RECRUITING | Congenital Heart Disease |
Subodh Verma |
2026-05-29 | PHASE3 |
| NCT06024746 | RECRUITING | Heart Failure |
Colorado Prevention Center |
2024-07-09 | PHASE3 |
| NCT07749014 | NOT_YET_RECRUITING | ST-elevation Myocardial Infarction (STEMI); Acute Myocardial Infarction (AMI); Coronary Artery Disease |
Rehman Medical Institute - RMI |
2026-09-01 | PHASE2 |
| NCT06613854 | RECRUITING | Type 2 Diabetes Mellitus (T2DM) |
University Medical Centre Ljubljana |
2024-10-01 | PHASE4 |
| NCT07141355 | RECRUITING | Cardiogenic Shock |
University Hospital, Strasbourg, France |
2025-12-12 | |
| NCT07146880 | NOT_YET_RECRUITING | Brugada Syndrome (BrS) |
National Taiwan University Hospital |
2025-09-15 | PHASE2 |
| NCT07776054 | RECRUITING | Atrial Fibrillation; SGLT2 Inhibitor; DC Cardioversion |
Samsung Medical Center |
2024-02-01 | PHASE4 |
| NCT07365358 | NOT_YET_RECRUITING | Diabete Type 2 |
Chong Kun Dang Pharmaceutical |
2026-03 | PHASE4 |
| NCT07155694 | NOT_YET_RECRUITING | Diabetic Kidney Disease |
Washington D.C. Veterans Affairs Medical Center |
2026-10-01 | PHASE4 |
| NCT06528405 | RECRUITING | Acute Kidney Injury |
National Taiwan University Hospital |
2024-11-21 | PHASE2 |
| NCT07292909 | RECRUITING | CAD - Coronary Artery Disease; Inflamation; PCI; SGLT 2 Inhibitors |
Hotel Dieu de France Hospital |
2025-09-01 | PHASE4 |
| NCT07053293 | RECRUITING | Type 2 Diabetes |
The University of Texas Health Science Center at San Antonio |
2025-01-07 | EARLY_PHASE1 |
| NCT07053319 | RECRUITING | Type 2 Diabetes |
The University of Texas Health Science Center at San Antonio |
2026-05-11 | PHASE1 |
| NCT05960656 | RECRUITING | Type 2 Diabetes |
The University of Texas Health Science Center at San Antonio |
2023-10-05 | PHASE1 |
| NCT07053306 | RECRUITING | Type 2 Diabetes |
The University of Texas Health Science Center at San Antonio |
2025-04-29 | PHASE1 |
| NCT06729996 | RECRUITING | Pancreatitis, Chronic; Pancreatitis, Acute; Diabetes Mellitus |
Mayo Clinic |
2025-05-29 | PHASE2 |
| NCT05138575 | RECRUITING | Heart Failure With Preserved Ejection Fraction |
University of Pennsylvania |
2022-01-24 | PHASE2 |
| NCT05715814 | RECRUITING | Peritoneal Dialysis Complication; End Stage Kidney Disease; Sodium-glucose Co-transporter-2 Inhibitors; Kidney Dysfunction; Residual Kidney Function |
University Health Network, Toronto |
2024-09-01 | PHASE3 |
| NCT06391450 | ACTIVE_NOT_RECRUITING | Autosomal Dominant Polycystic Kidney |
Hannover Medical School |
2024-06-14 | PHASE4 |
| NCT07038356 | RECRUITING | Acute Decompensated Heart Failure (ADHF) |
Christian Schulze |
2025-12-08 | PHASE3 |
| NCT07678151 | NOT_YET_RECRUITING | Hypertension (HTN) |
Heart Health Research Center |
2026-07-13 | |
| NCT07107945 | RECRUITING | Chronic Kidney Disease |
Boehringer Ingelheim |
2025-12-09 | PHASE3 |
| NCT07442006 | RECRUITING | Type 2 Diabetes Mellitus (T2DM) |
JW Pharmaceutical |
2025-10-29 | PHASE4 |
| NCT06643442 | NOT_YET_RECRUITING | DMD-associated Dilated Cardiomyopathy |
Sebastiano Lava |
2025-10-01 | PHASE2 |
| NCT05879276 | RECRUITING | Cardiogenic Shock |
Central Hospital, Nancy, France |
2024-12-16 | PHASE3 |
| NCT06473844 | RECRUITING | Sepsis; Inflammation; SGLT2 Inhibitors; Critically Ill; Organ Dysfunction Syndrome |
Hospital Authority, Hong Kong |
2025-03-05 | |
| NCT07372040 | RECRUITING | Acute Decompensated Heart Failure |
Tanta University |
2026-02-01 | PHASE2 |
| NCT06894784 | RECRUITING | Diabetes Type 1 |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2025-04 | PHASE3 |
| NCT06260059 | RECRUITING | Adult Congenital Heart Disease; Heart Failure |
Anita Saraf |
2024-09-17 | PHASE4 |
| NCT05671991 | RECRUITING | End Stage Renal Disease on Dialysis |
Yale University |
2023-03-01 | PHASE4 |
| NCT06519448 | ENROLLING_BY_INVITATION | Non-alcoholic Steatohepatitis; Liver Diseases; Diabetes Mellitus, Type 2; Fibrosis, Liver |
Military University Hospital, Prague |
2024-04-01 | |
| NCT05392764 | RECRUITING | Acute Heart Failure |
Juntendo University |
2022-09-10 | PHASE3 |
| NCT06989723 | RECRUITING | Type 2 Diabetes; Fatty Liver |
Seoul National University Bundang Hospital |
2025-01-01 | PHASE4 |
| NCT05164263 | RECRUITING | Type II Diabetes Mellitus; Efficacy, Self; Safety Issues |
Getz Pharma |
2021-04-01 | PHASE4 |
| NCT06055452 | RECRUITING | Pre-Heart Failure; Hypertension |
China National Center for Cardiovascular Diseases |
2024-01-19 | PHASE4 |
| NCT07336797 | RECRUITING | Metabolic Syndrome; Obesity & Overweight; HIV (Human Immunodeficiency Virus) |
Abdelrahman Mahmoud |
2025-09-01 | PHASE2 |
| NCT05786443 | RECRUITING | End Stage Renal Disease |
NYU Langone Health |
2024-01-31 | PHASE2 |
| NCT07700940 | RECRUITING | Lupus Nephritis (LN) |
Ahmed Yehia Ismail |
2024-01-22 | PHASE4 |
| NCT07692256 | RECRUITING | Heart Failure |
Ain Shams University |
2025-12-01 | PHASE2 |
| NCT05726032 | RECRUITING | Cirrhosis; Liver Failure |
Yale University |
2023-09-11 | PHASE2 |
| NCT06554301 | RECRUITING | Pulmonary Arterial Hypertension |
China National Center for Cardiovascular Diseases |
2024-10-20 | PHASE1 |
| NCT07093476 | RECRUITING | T2DM; Diabete Type 2; DM |
Celltrion |
2025-07-18 | PHASE3 |
| NCT07311551 | NOT_YET_RECRUITING | Type 2 Diabetes |
Bhavya Bhavya, MD |
2025-12-24 | PHASE4 |
| NCT06030843 | RECRUITING | Empagliflozin in Cardiorenal Syndrome Type 1 |
Chulalongkorn University |
2025-03-01 | PHASE2; PHASE3 |
| NCT05057806 | RECRUITING | Type2 Diabetes; Heart Failure With Preserved Ejection Fraction |
The University of Texas Health Science Center at San Antonio |
2021-01-13 | EARLY_PHASE1 |
| NCT06229678 | RECRUITING | Type2diabetes; Heart Failure With Reduced Ejection Fraction |
The University of Texas Health Science Center at San Antonio |
2024-01-25 | EARLY_PHASE1 |
| NCT05182658 | ACTIVE_NOT_RECRUITING | Hypertrophic Cardiomyopathy; Heart Failure |
National Institute of Cardiology, Warsaw, Poland |
2022-06-01 | PHASE3 |
| NCT05972564 | RECRUITING | Obesity; Metabolic Syndrome |
Vanderbilt University Medical Center |
2023-09-06 | PHASE1; PHASE2 |
| NCT04447911 | RECRUITING | Hyponatremia; SIADH; Liver Failure; Kidney Failure |
University Hospital, Basel, Switzerland |
2021-02-04 | PHASE4 |
| NCT06430684 | RECRUITING | Chronic Kidney Diseases; Pediatric Kidney Disease |
Ann & Robert H Lurie Children's Hospital of Chicago |
2024-08-23 | EARLY_PHASE1 |
| NCT05501483 | RECRUITING | Type 2 Diabetes |
Karolinska Institutet |
2023-02-08 | |
| NCT07472920 | NOT_YET_RECRUITING | Bipolar Disorder; Bipolar Depression; Insulin Resistance |
University of Sao Paulo |
2026-03-09 | |
| NCT06926660 | COMPLETED | Chronic Kidney Disease |
Boehringer Ingelheim |
2025-07-18 | PHASE2 |
| NCT06570473 | RECRUITING | Pulmonary Hypertension; Right Ventricular Dysfunction; Right Heart Failure |
University of Alberta |
2025-07-15 | PHASE2 |
| NCT07065357 | ENROLLING_BY_INVITATION | Metabolic Syndrome |
The University of Hong Kong |
2025-08-13 | PHASE3 |
| NCT06483074 | RECRUITING | End Stage Renal Disease on Dialysis; Peritoneal Dialysis Complication; Sodium-glucose Cotransporter-2 Inhibitor; Residual Kidney Function |
Chinese University of Hong Kong |
2024-07-29 | PHASE2 |
| NCT06469645 | COMPLETED | Moderate Aortic Valve Stenosis |
University of East Anglia |
2024-05-30 | PHASE2; PHASE3 |
| NCT07214818 | RECRUITING | Nephrotic Syndrome |
Mansoura University |
2025-11-15 | PHASE2; PHASE3 |
| NCT05028140 | RECRUITING | Type II Diabetes |
EMS |
2024-10-08 | PHASE3 |
| NCT04670666 | RECRUITING | Type 2 Diabetes Mellitus |
EMS |
2024-11-18 | PHASE3 |
| NCT06715449 | RECRUITING | Embolic Stroke of Undetermined Source; Atrial Fibrillation New Onset |
University of East Anglia |
2024-11-22 | PHASE2; PHASE3 |
| NCT06851962 | COMPLETED | Diabetes Mellitus Type 2 |
Fundación para la Investigación del Hospital Clínico de Valencia |
2025-05-26 | PHASE4 |
| NCT07694115 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
Humanis Saglık Anonim Sirketi |
2026-05-07 | PHASE1 |
| NCT07691203 | COMPLETED | Type 2 Diabetes Mellitus (T2DM); Cardiovascular Diseases |
Humanis Saglık Anonim Sirketi |
2026-03-07 | PHASE1 |
| NCT05757791 | COMPLETED | Major Depressive Disorder |
NYU Langone Health |
2023-03-17 | PHASE2 |
| NCT06706791 | RECRUITING | Chronic Heart Failure |
Fazaia Ruth Pfau Medical College |
2025-04-01 | PHASE4 |
| NCT05669742 | RECRUITING | Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics |
Tanta University |
2023-05-25 | PHASE3 |
| NCT05553938 | ACTIVE_NOT_RECRUITING | Heart Failure |
Yale University |
2023-08-04 | PHASE1 |
| NCT06171802 | COMPLETED | Aortic Valve Stenosis |
Rigshospitalet, Denmark |
2024-02-14 | PHASE4 |
| NCT05687058 | ACTIVE_NOT_RECRUITING | Kidney Failure, Chronic; Heart Failure |
University of Mississippi Medical Center |
2023-11-01 | PHASE1; PHASE2 |
| NCT05174507 | WITHDRAWN | Postprandial Hypoglycemia |
University Hospital, Basel, Switzerland |
2022-06-24 | PHASE2 |
| NCT04602754 | RECRUITING | Dyslipidemia Associated With Type II Diabetes Mellitus |
EMS |
2023-12-01 | PHASE3 |
| NCT06862739 | RECRUITING | Diabetes Mellitus; Type 2 DM |
Nabiqasim Industries (Pvt) Ltd |
2025-10-30 | PHASE4 |
| NCT05426525 | COMPLETED | PreDiabetes; Prediabetic State; Overweight and Obesity |
Oregon State University |
2022-10-13 | PHASE4 |
| NCT06571591 | COMPLETED | T2DM |
Celltrion |
2024-08-27 | PHASE3 |
| NCT07452913 | ENROLLING_BY_INVITATION | Type 2 Diabetes Mellitus |
Bahria University |
2026-01-01 | PHASE4 |
| NCT05510115 | ACTIVE_NOT_RECRUITING | Polycystic Kidney, Autosomal Dominant |
University of Colorado, Denver |
2022-11-18 | PHASE2 |
| NCT06342141 | ACTIVE_NOT_RECRUITING | STEMI; No-Reflow Phenomenon |
Instituto Nacional de Cardiologia Ignacio Chavez |
2024-08-22 | PHASE2 |
| NCT07379788 | COMPLETED | Heart Failure |
Rehab Werida |
2025-01-01 | |
| NCT06844669 | TERMINATED | HER2-positive Breast Cancer; HER2+ Breast Cancer |
Washington University School of Medicine |
2025-04-16 | PHASE2 |
| NCT05305495 | COMPLETED | Acute Heart Failure; Chronic Kidney Diseases |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2022-12-22 | PHASE4 |
| NCT06618976 | COMPLETED | Thrombosis |
Icahn School of Medicine at Mount Sinai |
2025-02-25 | PHASE4 |
| NCT07180745 | NOT_YET_RECRUITING | Non-alcoholic Fatty Liver Disease NAFLD; Non-alcoholic Steatohepatitis NASH |
Badr University |
2025-11-01 | PHASE4 |
| NCT05885074 | WITHDRAWN | Obesity; Weight Loss |
University of Alabama at Birmingham |
2025-01-30 | PHASE2 |
| NCT04906213 | TERMINATED | Kidney Transplant; Complications; Diabetes Mellitus, Type 2 |
Duke University |
2022-07-25 | PHASE2 |
| NCT06762314 | COMPLETED | Diabetes |
Mostafa Bahaa |
2025-01-20 | PHASE2 |
| NCT07331389 | RECRUITING | Overweight Subject; Healthy Subjects |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
2025-09-24 | PHASE1 |
| NCT05905965 | UNKNOWN | Metabolic Syndrome |
Collegium Medicum w Bydgoszczy |
2023-05-01 | PHASE3 |
| NCT05313529 | COMPLETED | Type 2 Diabetes Mellitus; Mild Cognitive Impairment |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2022-10-08 | |
| NCT07372118 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
Humanis Saglık Anonim Sirketi |
2025-09-27 | PHASE1 |
| NCT05638880 | COMPLETED | Diabetic Nephropathies |
Mostafa Bahaa |
2022-12-20 | PHASE2 |
| NCT05610956 | RECRUITING | Ulcerative Colitis |
Tanta University |
2023-01-01 | EARLY_PHASE1 |
| NCT07531108 | COMPLETED | Diabetes Mellitus, Type 2 |
Hawler Medical University |
2024-11-15 | PHASE4 |
| NCT07633054 | COMPLETED | Bioequivalence Study in Healthy Subjects |
ADIUM |
2025-09-10 | |
| NCT07591077 | COMPLETED | Type 1 Diabetes; Nephropathy, Diabetic |
Ain Shams University |
2024-11-20 | PHASE2; PHASE3 |
| NCT07541456 | COMPLETED | Type 2 Diabetes Mellitus; Hypertension |
Dr. Zarmina Younes |
2025-06-09 | PHASE4 |
| NCT07133399 | COMPLETED | Healthy |
Boehringer Ingelheim |
2025-09-08 | PHASE1 |
| NCT07102719 | COMPLETED | Healthy Volunteers |
Handok Inc. |
2025-09-10 | PHASE1 |
| NCT06095492 | RECRUITING | Kidney Transplant; Complications; Diabetes Mellitus |
Medanta, The Medicity, India |
2023-10-30 | |
| NCT06818305 | TERMINATED | Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC); Nephrectomy; Chronic Kidney Disease(CKD) |
Jinling Hospital, China |
2025-01-01 | PHASE2 |
| NCT06846411 | RECRUITING | Diabetes; Diabetes Mellitus, Type II |
Seoul National University Bundang Hospital |
2024-01-01 | PHASE4 |
| NCT05058417 | WITHDRAWN | Ulcerative Colitis |
Sadat City University |
2021-10-01 | PHASE2 |
| NCT06410352 | RECRUITING | Metabolic Syndrome |
University Medical Center, Kazakhstan |
2024-03-01 | PHASE4 |
| NCT06094920 | COMPLETED | Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus, Type 2; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; CKD; CKD Stage 3; CKD Stage 4 |
University Medical Center Groningen |
2024-07-29 | PHASE4 |
| NCT07266766 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
Humanis Saglık Anonim Sirketi |
2025-08-05 | PHASE1 |
| NCT07213895 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
Humanis Saglık Anonim Sirketi |
2025-05-21 | PHASE1 |
| NCT06828731 | COMPLETED | Prediabetes |
Charles George VA Medical Center |
2024-12-06 | PHASE1 |
| NCT07120828 | COMPLETED | Type 2 Diabetes; Obese Diabetics; Obese Patients (BMI ≥ 30 kg/m²) |
Erbil Polytechnic University |
2025-07-15 | PHASE4 |
| NCT07035457 | COMPLETED | Healthy |
Boehringer Ingelheim |
2025-07-02 | PHASE1 |
| NCT06012266 | UNKNOWN | Heart Failure |
Centre Hospitalier Universitaire Vaudois |
2024-08 | PHASE2 |
| NCT04918407 | COMPLETED | Kidney Transplant; Complications |
Shahid Beheshti University of Medical Sciences |
2022-01-01 | |
| NCT06435858 | RECRUITING | Autosomal Dominant Polycystic Kidney Disease |
Cantonal Hospital Graubuenden |
2024-09-01 | PHASE2 |
| NCT07303556 | ACTIVE_NOT_RECRUITING | Heart Failure; Diabete Type 2; Arterial Hypertension |
Nazarbayev University |
2024-12-18 | |
| NCT06098625 | UNKNOWN | Diabetes Mellitus; Kidney Transplant; Complications |
Medanta, The Medicity, India |
2023-11-10 | |
| NCT05614115 | COMPLETED | End-stage Kidney Disease; Kidney Disease, Chronic; Dialysis; Diabetic; Non-diabetic; Kidney Dysfunction; Kidney Failure; Hemodialysis |
University of Utah |
2023-03-21 | PHASE1 |
| NCT07112274 | COMPLETED | Heart Failure |
Damanhour University |
2022-10-01 | |
| NCT06962826 | COMPLETED | Healthy |
Boehringer Ingelheim |
2025-05-27 | PHASE1 |
| NCT06149793 | ACTIVE_NOT_RECRUITING | Cystic Fibrosis-related Diabetes; Cystic Fibrosis |
University of Minnesota |
2024-01-08 | PHASE2; PHASE3 |
| NCT05967156 | COMPLETED | Heart Failure; Hemodialysis |
Shahid Beheshti University of Medical Sciences |
2023-06-01 | |
| NCT06823856 | COMPLETED | Diabetes Mellitus Type 2 |
Gedeon Richter Plc. |
2025-05-11 | PHASE1 |
| NCT07039890 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
Humanis Saglık Anonim Sirketi |
2025-03-08 | PHASE1 |
| NCT07556094 | COMPLETED | Obstructive Sleep Apnea (OSA); Sleep Apnea Syndrome, Obstructive; Heart Failure |
Medical University of Bialystok |
2023-06-05 | |
| NCT05078879 | COMPLETED | Crohn's Disease; Glycogen Metabolism; Inflammatory Bowel Disease (IBD) |
National Institute of Allergy and Infectious Diseases (NIAID) |
2021-11-16 | PHASE1 |
| NCT06187285 | COMPLETED | Type 2 Diabetes |
Medanta, The Medicity, India |
2024-01-01 | |
| NCT06021145 | UNKNOWN | Type 1 Diabetes |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2024-04-02 | PHASE4 |
| NCT07633015 | COMPLETED | Bioequivalence Study in Healthy Subjects |
ADIUM |
2025-02-17 | |
| NCT06889350 | COMPLETED | Healthy Volunteers |
Handok Inc. |
2025-03-26 | PHASE1 |
| NCT07633028 | COMPLETED | Bioequivalence Study in Healthy Subjects |
ADIUM |
2025-02-10 | |
| NCT06792968 | COMPLETED | Diabetes Mellitus Type 2 |
Gedeon Richter Plc. |
2025-03-30 | PHASE1 |
| NCT07633041 | COMPLETED | Bioequivalence Study in Healthy Subjects |
ADIUM |
2025-02-05 | |
| NCT04603508 | UNKNOWN | Type 2 Diabetes Mellitus; Dyslipidemia |
EMS |
2023-03 | PHASE3 |
| NCT07367555 | COMPLETED | Diabete Mellitus |
Ariba Shafiq |
2024-10-01 | PHASE1 |
| NCT06759922 | COMPLETED | Type 2 Diabetes Mellitus |
Bahria University |
2025-01-01 | PHASE4 |
| NCT05254002 | COMPLETED | Type 2 Diabetes Mellitus; Chronic Kidney Disease |
Bayer |
2022-06-23 | PHASE2 |
| NCT06641128 | NOT_YET_RECRUITING | Rheumatoid Arthritis (RA); Methotrexate Induced Nephrotoxicity; Methotrexate Adverse Reaction |
Tanta University |
2024-10-15 | PHASE4 |
| NCT06932159 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
Humanis Saglık Anonim Sirketi |
2024-12-23 | PHASE1 |
| NCT06766500 | COMPLETED | Diabetes Mellitus Type 2 |
Gedeon Richter Plc. |
2025-01-20 | PHASE1 |
| NCT07169981 | COMPLETED | Diabete Mellitus; Heart Failure; Remodeling, Left Ventricle |
Ain Shams University |
2023-07-12 | PHASE2 |
| NCT04639414 | COMPLETED | Type 2 Diabetes; Non-alcoholic Steatohepatitis (NASH); Non-alcoholic Fatty Liver Disease (NAFLD) |
German Diabetes Center |
2021-03-26 | PHASE4 |
| NCT06187493 | UNKNOWN | Diabetic Kidney Disease |
Assiut University |
2024-01-01 | |
| NCT06083675 | WITHDRAWN | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2024-01-26 | PHASE3 |
| NCT05042973 | COMPLETED | Obesity; Heart Failure |
Jacob Moller |
2021-09-02 | PHASE2 |
| NCT05084235 | COMPLETED | Heart Failure; Obesity |
Jacob Moller |
2021-09-02 | PHASE2 |
| NCT06915870 | COMPLETED | Diabetes Mellitus; Heart Failure |
Fatima Maqsood |
2024-07-12 | |
| NCT04970108 | WITHDRAWN | Hypertension Associated; Type II Diabetes Mellitus |
EMS |
2023-08 | PHASE3 |
| NCT03215069 | COMPLETED | Gestational Diabetes |
Mount Sinai Hospital, Canada |
2018-07-01 | PHASE3 |
| NCT06124937 | UNKNOWN | Post-operative Atrial Fibrillation; CABG |
Rajaie Cardiovascular Medical and Research Center |
2023-11-07 | PHASE3 |
| NCT07479108 | COMPLETED | Bioequivalance |
ADIUM |
2024-11-29 | |
| NCT06952231 | COMPLETED | Diabetes Mellitus |
University of Lahore |
2024-05-21 | PHASE3 |
| NCT06065280 | COMPLETED | Heart Failure; Reduced Ejection Fraction Heart Failure |
Damanhour University |
2022-11-01 | |
| NCT05493371 | COMPLETED | Idiopathic Pulmonary Arterial Hypertension |
Amsterdam UMC, location VUmc |
2023-03-01 | PHASE2 |
| NCT06350903 | COMPLETED | Myocardial Suppression |
Matthieu Pelletier-Galarneau, MD MSc |
2024-06-01 | |
| NCT05444153 | WITHDRAWN | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2022-10-06 | PHASE3 |
| NCT05600387 | UNKNOWN | Heart Failure; Heart Failure With Preserved Ejection Fraction; Heart Failure With Mid Range Ejection Fraction |
Zhijun Sun |
2022-11-05 | PHASE4 |
| NCT05584319 | UNKNOWN | Heart Failure; Heart Failure With Preserved Ejection Fraction |
Zhijun Sun |
2022-12-15 | PHASE4 |
| NCT06313008 | COMPLETED | Coronary Artery Disease; Type 2 Diabetes |
Damanhour University |
2023-08-10 | |
| NCT05776043 | UNKNOWN | Acute Decompensated Heart Failure |
Medical University of Warsaw |
2022-03-15 | PHASE3 |
| NCT05081219 | COMPLETED | Mild Cognitive Impairment; Cognitive Impairment; Alzheimer Disease |
Wake Forest University Health Sciences |
2021-09-14 | PHASE2 |
| NCT06578676 | UNKNOWN | Type 2 Diabetes; Dyslipidemias |
Hyundai Pharm |
2024-06-20 | PHASE1 |
| NCT06046612 | UNKNOWN | Heart Failure With Preserved Ejection Fraction; Microvascular Dysfunction |
Maastricht University Medical Center |
2023-02-13 | PHASE4 |
| NCT05036317 | TERMINATED | Postprandial Hypoglycemia |
University Hospital, Basel, Switzerland |
2022-03-11 | PHASE3 |
| NCT06401343 | UNKNOWN | Hypertrophic Cardiomyopathy; Heart Failure With Preserved Ejection Fraction |
China National Center for Cardiovascular Diseases |
2022-08-01 | PHASE4 |
| NCT06012266 | Not yet recruiting | Heart Failure |
Centre Hospitalier Universitaire Vaudois|Great Ormond Street Hospital for Children NHS Foundation Trust|University College London |
2024-08 | Phase 2 |
| NCT06337409 | UNKNOWN | Healthy Volunteer |
International Bio service |
2024-07-01 | PHASE1 |
| NCT06103279 | UNKNOWN | Cancer |
Ain Shams University |
2023-11 | PHASE2; PHASE3 |
| NCT05960617 | WITHDRAWN | Glycogen Storage Disease Type IB |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2023-07-15 | PHASE2 |
| NCT05140694 | UNKNOWN | Metabolic-associated Fatty Liver Disease; Type 2 Diabetes |
Seoul National University Bundang Hospital |
2023-12-01 | PHASE4 |
| NCT05778084 | UNKNOWN | Heart Failure With Reduced Ejection Fraction |
Alexandria University |
2022-12-15 | PHASE4 |
| NCT06339788 | COMPLETED | Healthy Volunteers |
Handok Inc. |
2024-05-10 | PHASE1 |
| NCT05020704 | UNKNOWN | Myocardial Infarction |
NHS Greater Glasgow and Clyde |
2022-09-16 | PHASE3 |
| NCT04345796 | COMPLETED | Tricuspid Regurgitation; Right Ventricular Dilatation |
Asan Medical Center |
2021-02-15 | PHASE3 |
| NCT05545800 | UNKNOWN | Type 2 Diabetes Mellitus |
Xiangya Hospital of Central South University |
2022-09-01 | PHASE3 |
| NCT05360615 | ACTIVE_NOT_RECRUITING | Empagliflozin in Post AKI Stage 2-3 |
Chulalongkorn University |
2022-07-01 | PHASE1 |
| NCT04930627 | UNKNOWN | Glucose 6 Phosphatase Deficiency |
Children's Memorial Health Institute, Poland |
2021-07 | PHASE2 |
| NCT06308679 | UNKNOWN | Healthy Vollunteer |
Pharma Nueva |
2024-05-28 | PHASE1 |
| NCT06140108 | COMPLETED | Polycystic Ovary Syndrome; Weight Gain; HbA1c |
SINA Health Education and Welfare Trust |
2023-12-15 | PHASE2; PHASE3 |
| NCT04541797 | ACTIVE_NOT_RECRUITING | Type 2 Diabetes; Microvascular Coronary Artery Disease |
The University of Hong Kong |
2020-10-01 | |
| NCT05129722 | TERMINATED | Heart Failure With Preserved Ejection Fraction |
The George Institute |
2022-10-01 | PHASE4 |
| NCT06308679 | Not yet recruiting | Healthy Vollunteer |
Pharma Nueva |
2024-05-28 | Phase 1 |
| NCT06683053 | ACTIVE_NOT_RECRUITING | Congestive Heart Failure (CHF) |
Conrado Roberto Hoffmann Filho |
2023-03-17 | PHASE3 |
| NCT05282121 | TERMINATED | Liver Diseases; Hypertension, Portal |
Boehringer Ingelheim |
2022-06-28 | PHASE2 |
| NCT05504239 | COMPLETED | Type 2 Diabetes |
Handok Inc. |
2022-09-27 | PHASE3 |
| NCT06232239 | UNKNOWN | Healthy Subjects |
Bio-innova Co., Ltd |
2024-02-27 | PHASE1 |
| NCT05373680 | COMPLETED | Renal Insufficiency, Chronic |
Tanta University |
2022-01-01 | PHASE2; PHASE3 |
| NCT06339788 | Not yet recruiting | Healthy Volunteers |
Handok Inc. |
2024-04 | Phase 1 |
| NCT06013865 | Recruiting | Kidney Transplant|Type 2 Diabetes |
VA Office of Research and Development|Iowa City VA Health Care System|VA Pittsburgh Healthcare System|Nashville VA Medical Center |
2024-04-05 | Phase 4 |
| NCT05942963 | UNKNOWN | Non-Alcoholic Fatty Liver Disease; Type2diabetes |
Jinnah Postgraduate Medical Centre |
2023-10 | PHASE4 |
| NCT03912909 | UNKNOWN | Metabolic Syndrome; Type 2 Diabetes Mellitus; Obesity |
Royal Perth Hospital |
2018-08-01 | PHASE4 |
| NCT04117763 | COMPLETED | Diabetes Mellitus, Type 2; Coronary Heart Disease; Arrythmia, Cardiac |
University of Sao Paulo |
2019-10-04 | PHASE4 |
| NCT05232071 | COMPLETED | NASH - Nonalcoholic Steatohepatitis; Diabetes Mellitus, Type 2 |
Inventiva Pharma |
2022-06-29 | PHASE2 |
| NCT06145360 | COMPLETED | Glucose Metabolism Disorders; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Empagliflozin |
SINA Health Education and Welfare Trust |
2023-12-01 | PHASE4 |
| NCT05373004 | UNKNOWN | Diabetic Nephropathy Type 2 |
Omar Tarek Elfarargi |
2023-03 | PHASE2; PHASE3 |
| NCT06021145 | Recruiting | Type 1 Diabetes |
McGill University Health Centre/Research Institute of the McGill University Health Centre|Diabetes Canada |
2024-03 | Phase 4 |
| NCT05556044 | UNKNOWN | Acute Heart Failure |
Chinese University of Hong Kong |
2022-09-27 | PHASE3 |
| NCT05694923 | COMPLETED | Fatty Liver Disease |
Assiut University |
2023-04-01 | |
| NCT04523064 | COMPLETED | Diabetes Mellitus, Type 2; Coronary Artery Disease; Coronary Artery Bypass Surgery; Acute Kidney Injury |
University of Sao Paulo General Hospital |
2020-09-22 | PHASE4 |
| NCT06450262 | COMPLETED | Type2diabetes |
Humanis Saglık Anonim Sirketi |
2024-01-04 | PHASE1 |
| NCT04583813 | UNKNOWN | Atrial Fibrillation; Heart Failure; Obesity; Diabetes Mellitus |
Miulli General Hospital |
2021-09 | PHASE4 |
| NCT04796428 | UNKNOWN | Diabetes Mellitus, Type 2 |
Center for Outcomes Research and Clinical Epidemiology, Italy |
2021-06-30 | PHASE4 |
| NCT03877406 | UNKNOWN | Diabetes Mellitus; Fat; Intolerance, Pancreas |
Seoul National University Bundang Hospital |
2018-08-01 | PHASE4 |
| NCT04907214 | COMPLETED | Obesity; Pre-diabetes |
Vanderbilt University Medical Center |
2021-07-29 | PHASE1; PHASE2 |
| NCT06204107 | COMPLETED | Type 2 Diabetes Mellitus |
Chong Kun Dang Pharmaceutical |
2023-11-21 | PHASE1 |
| NCT05364190 | COMPLETED | Chronic Heart Failure; Acute Heart Failure; Diabetes Mellitus |
October 6 University |
2022-06-04 | PHASE3 |
| NCT05504226 | COMPLETED | Type 2 Diabetes |
Handok Inc. |
2022-10-12 | PHASE3 |
| NCT04509674 | COMPLETED | Myocardial Infarction |
Boehringer Ingelheim |
2020-12-16 | PHASE3 |
| NCT04203927 | UNKNOWN | Type2 Diabetes; Insulin Sensitivity |
University of Virginia |
2020-02-01 | EARLY_PHASE1 |
| NCT04535960 | UNKNOWN | Type 2 Diabetes Mellitus |
University Health Network, Toronto |
2019-01-24 | PHASE2 |
| NCT05139472 | COMPLETED | Heart Failure with Preserved Ejection Fraction; Heart Failure, Diastolic; Diabetes Mellitus |
University of Texas Southwestern Medical Center |
2021-11-09 | PHASE4 |
| NCT07363707 | COMPLETED | NAFLD (Nonalcoholic Fatty Liver Disease) |
Beni-Suef University |
2023-05-01 | PHASE4 |
| NCT06180109 | COMPLETED | Type2 Diabetes Mellitus |
Humanis Saglık Anonim Sirketi |
2023-07-30 | PHASE1 |
| NCT05977465 | COMPLETED | Diabetic Neuropathy Peripheral |
Tanta University |
2022-01-20 | PHASE1; PHASE2 |
| NCT05580510 | UNKNOWN | Congenital Heart Disease; Heart Failure; Heart Failure With Reduced Ejection Fraction |
Instituto Nacional de Cardiologia Ignacio Chavez |
2023-02-06 | PHASE2; PHASE3 |
| NCT05182840 | COMPLETED | Kidney Disease, Chronic |
Boehringer Ingelheim |
2022-01-11 | PHASE2 |
| NCT05417646 | COMPLETED | Maturity-Onset Diabetes of the Young, Type 3; Type 2 Diabetes |
Steno Diabetes Center Copenhagen |
2022-06-22 | |
| NCT04642261 | COMPLETED | Non-alcoholic Fatty Liver Disease |
The University of Hong Kong |
2021-01-01 | PHASE4 |
| NCT05013502 | COMPLETED | Liver Cirrhosis; Cirrhosis; Ascites; Ascites Hepatic; Sodium-Glucose Transporter 2 Inhibitors |
Stanford University |
2021-11-15 | PHASE1 |
| NCT06825156 | COMPLETED | Acute Kidney Injury |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2022-03-03 | PHASE4 |
| NCT04976283 | UNKNOWN | Diabetes Mellitus, Type 2; NASH - Nonalcoholic Steatohepatitis; NAFLD |
Getz Pharma |
2021-09-15 | PHASE4 |
| NCT03437330 | WITHDRAWN | Type2 Diabetes Mellitus |
University Hospital Tuebingen |
2021-10-27 | PHASE4 |
| NCT05233163 | COMPLETED | Transthyretin Amyloid Cardiomyopathy |
Columbia University |
2022-03-14 | PHASE4 |
| NCT05605158 | UNKNOWN | Non Alcoholic Steatohepatitis |
Tanta University |
2022-11 | PHASE3 |
| NCT04911660 | COMPLETED | Kidney Stone |
Insel Gruppe AG, University Hospital Bern |
2021-08-25 | PHASE2 |
| NCT05681273 | COMPLETED | T2DM |
Chipscreen Biosciences, Ltd. |
2023-02-17 | PHASE1 |
| NCT07247656 | COMPLETED | Diabete Mellitus |
Bahria University |
2022-12-01 | PHASE4 |
| NCT05512130 | UNKNOWN | Epilepsy |
Washington University School of Medicine |
2022-08-17 | EARLY_PHASE1 |
| NCT05417880 | UNKNOWN | Diabetes Mellitus |
Scotmann Pharmaceuticals |
2022-08 | PHASE3 |
| NCT03193684 | COMPLETED | Hepatic Glucose Metabolism |
The University of Texas Health Science Center at San Antonio |
2018-05-20 | PHASE4 |
| NCT04662866 | UNKNOWN | Impaired Glucose Tolerance; Insulin Sensitivity; Glucose Metabolism Disorders |
Oslo University Hospital |
2021-02-10 | PHASE2 |
| NCT05956522 | COMPLETED | Healthy |
The Affiliated Hospital of Qingdao University |
2022-07-01 | PHASE1 |
| NCT05430243 | COMPLETED | Ascites Hepatic |
Alexandria University |
2022-04-21 | PHASE2; PHASE3 |
| NCT03429543 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2018-03-20 | PHASE3 |
| NCT04531462 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2020-10-05 | PHASE4 |
| NCT05057819 | COMPLETED | Dumping Syndrome; Hypoglycemia, Reactive |
Insel Gruppe AG, University Hospital Bern |
2021-12-01 | PHASE4 |
| NCT04461041 | COMPLETED | Cardiovascular Diseases; Left Ventricular Hypertrophy |
Unity Health Toronto |
2021-04-01 | PHASE4 |
| NCT03594110 | COMPLETED | Chronic Kidney Disease |
Boehringer Ingelheim |
2019-01-31 | PHASE3 |
| NCT05200793 | UNKNOWN | Polycystic Ovary Syndrome (PCOS) |
Alexandria University |
2021-12-07 | PHASE4 |
| NCT05037695 | UNKNOWN | Diabetes Mellitus, Type 2; Coronary Artery Disease; Acute Kidney Injury |
University of Sao Paulo General Hospital |
2021-07-21 | PHASE4 |
| NCT03646292 | COMPLETED | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Type 2 Diabetes; Digestive System Disease; Liver Diseases; Fatty Liver; Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-Alcoholic Fatty Liver Disease; Hypoglycemic Agents; Physiological Effects of Drugs; Sodium-Glucose Cotransporter 2 Inhibitors; Pioglitazone; Molecular Mechanisms of Pharmacological Action; Empagliflozin; Thiazolidinediones |
Yonsei University |
2018-12-06 | PHASE4 |
| NCT05109949 | UNKNOWN | Diabetes Mellitus Type 2 Without Complication |
Centro Universitario de Ciencias de la Salud, Mexico |
2020-03-30 | PHASE3 |
| NCT04917692 | WITHDRAWN | type1diabetes |
Ohio State University |
2021-07 | PHASE4 |
| NCT05036421 | COMPLETED | Pharmacogenomic; Pharmacokinetics |
Ain Shams University |
2022-02-15 | PHASE3 |
| NCT03087773 | COMPLETED | Acute Myocardial Infarction |
Medical University of Graz |
2017-05-11 | PHASE3 |
| NCT04702490 | UNKNOWN | NASH; NASH - Nonalcoholic Steatohepatitis; Type 2 Diabetes; Diabetes Type 2; Diabetes; Fatty Liver; Fatty Liver, Nonalcoholic; NAFLD |
Metacrine, Inc. |
2020-12-15 | PHASE2 |
| NCT05857085 | COMPLETED | Endothelial Dysfunction; Diabetes Mellitus, Type 1; Biomarkers; Endothelial Progenitor Cells; SGLT 2 Inhibitors; Incretins; Glucose Excursions; FMD; FPF; Arterial Stiffness |
General and Teaching Hospital Celje |
2021-12-15 | PHASE4 |
| NCT06632561 | COMPLETED | Heart Failure With Reduced Ejection Fraction |
Ashraf Wasfy Beshay Aziz |
2021-07-26 | PHASE4 |
| NCT04233801 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2020-04-15 | PHASE3 |
| NCT04243850 | WITHDRAWN | Diabetes Mellitus, Type 2; Chronic Kidney Diseases |
Amsterdam UMC, location VUmc |
2020-07-01 | PHASE4 |
| NCT04221152 | UNKNOWN | Insulin Resistance - Type A; Insulin Resistance - Type B; Lipoatrophic Diabetes Mellitus; Insulin Resistance Syndrome |
Kobe University |
2020-02-01 | PHASE3 |
| NCT04450563 | COMPLETED | Type 1 Diabetes |
McGill University |
2020-11-02 | PHASE1 |
| NCT04342819 | COMPLETED | Platelet Dysfunction Due to Drugs |
The University of The West Indies |
2020-01-01 | PHASE2; PHASE3 |
| NCT03753087 | COMPLETED | Heart Failure, Diastolic; Diabetes Mellitus, Type 2 |
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation |
2019-01-16 | PHASE4 |
| NCT05229796 | COMPLETED | Pharmacokinetic Parameters |
Mutah University |
2021-05-17 | |
| NCT04910178 | COMPLETED | Diabetes Type 2; NAFLD |
Asmaa Abdelfattah Elsayed |
2020-12-01 | PHASE4 |
| NCT04183868 | COMPLETED | Type 2 Diabetes; Cardiovascular Risk Factor |
University of Catanzaro |
2016-04 | PHASE4 |
| NCT05041673 | UNKNOWN | Fatty Liver, Nonalcoholic; Diabetes Mellitus, Type 2 |
Alexandria University |
2021-02-23 | |
| NCT05283057 | COMPLETED | Glomerulonephritis; Proteinuria |
Kasr El Aini Hospital |
2020-02-20 | PHASE3 |
| NCT04238702 | COMPLETED | Diabetes Mellitus, Type 2; Diabetic Kidney Disease |
Amsterdam UMC, location VUmc |
2020-11-04 | PHASE4 |
| NCT05359341 | COMPLETED | Diabete Type 2 |
Sadat City University |
2020-09-20 | |
| NCT04201496 | COMPLETED | Type 1 Diabetes |
Ananda Basu, MD |
2020-02-24 | PHASE1 |
| NCT04143581 | WITHDRAWN | Obesity; Non-diabetic Chronic Kidney Disease |
Mario Negri Institute for Pharmacological Research |
2021-09-03 | PHASE2 |
| NCT03979352 | COMPLETED | Type1 Diabetes Mellitus |
Samuel Lunenfeld Research Institute, Mount Sinai Hospital |
2019-08-01 | PHASE3 |
| NCT04961931 | UNKNOWN | Chronic Kidney Disease stage3 |
Medical University of Lodz |
2019-01-01 | |
| NCT04520646 | UNKNOWN | Acromegaly; Cardiomyopathies |
Huashan Hospital |
2020-09-01 | |
| NCT03202667 | COMPLETED | SIAD - Syndrome of Inappropriate Antidiuresis; Hyponatremia |
University Hospital, Basel, Switzerland |
2017-12-15 | PHASE2; PHASE3 |
| NCT05359432 | COMPLETED | Type 2 Diabetes |
Getz Pharma |
2020-07-01 | PHASE4 |
| NCT05083949 | COMPLETED | Healthy |
Boehringer Ingelheim |
2021-07-23 | PHASE1 |
| NCT04018365 | UNKNOWN | Insulin Resistance - Type A; Insulin Resistance - Type B; Lipoatrophic Diabetes Mellitus; Insulin Resistance Syndrome |
Kobe University |
2019-09-01 | PHASE3 |
| NCT04061200 | UNKNOWN | Type 2 Diabetes With Renal Manifestations |
Steno Diabetes Center Copenhagen |
2019-11-01 | PHASE4 |
| NCT03932721 | COMPLETED | Dyslipidemia Associated With Type II Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypertension Arterial |
University of Campinas, Brazil |
2018-10-01 | PHASE4 |
| NCT05210517 | COMPLETED | Type 2 Diabetes |
Amsterdam UMC, location VUmc |
2020-10-01 | PHASE4 |
| NCT03433248 | UNKNOWN | Type2 Diabetes |
M.H.H. Kramer |
2017-11-09 | PHASE4 |
| NCT04049045 | COMPLETED | Acute Decompensated Heart Failure |
Christian Schulze |
2019-09-29 | PHASE2 |
| NCT04157751 | COMPLETED | Heart Failure |
Boehringer Ingelheim |
2020-05-18 | PHASE3 |
| NCT03057951 | COMPLETED | Heart Failure |
Boehringer Ingelheim |
2017-03-02 | PHASE3 |
| NCT03560375 | COMPLETED | Diabetes Mellitus, Type 2; Sarcopenia; Weight Loss |
Tel-Aviv Sourasky Medical Center |
2018-05-09 | PHASE4 |
| NCT04131582 | UNKNOWN | Prediabetic State; Insulin Resistance |
Universidad de Guanajuato |
2019-09-01 | PHASE3 |
| NCT04431141 | COMPLETED | Type 2 Diabetes Mellitus |
Handok Inc. |
2020-09-15 | PHASE1 |
| NCT03852901 | COMPLETED | Empaglifozin; Physiological Effects of Drugs; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors |
National Institute on Aging (NIA) |
2019-03-28 | PHASE1 |
| NCT03554200 | TERMINATED | Diabetes Mellitus, Type 2; Acute Heart Failure |
RWTH Aachen University |
2018-06-11 | PHASE2 |
| NCT04665284 | COMPLETED | Type II Diabetes Mellitus |
Getz Pharma |
2019-06-01 | PHASE4 |
| NCT03933956 | TERMINATED | Diabetic Nephropathies |
Singapore General Hospital |
2020-01-09 | PHASE3 |
| NCT04014192 | UNKNOWN | Type 2 Diabetes Mellitus |
Peking Union Medical College Hospital |
2019-09-01 | PHASE4 |
| NCT04138251 | UNKNOWN | Glycogen Storage Disease Type I; Glucose 6 Phosphatase Deficiency |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2019-06-20 | PHASE2 |
| NCT04195243 | UNKNOWN | Type 2 Diabetes Mellitus |
Centro Universitario de Ciencias de la Salud, Mexico |
2019-12-02 | PHASE3 |
| NCT02932436 | COMPLETED | Diabetes Mellitus, Type 2; Diastolic Dysfunction |
Johannes Gutenberg University Mainz |
2016-10-10 | PHASE4 |
| NCT03151343 | COMPLETED | Type2 Diabetes Mellitus |
Caroline M Kistorp |
2017-03-29 | PHASE3 |
| NCT03332212 | COMPLETED | Heart Failure |
Boehringer Ingelheim |
2018-03-01 | PHASE3 |
| NCT03057977 | COMPLETED | Heart Failure |
Boehringer Ingelheim |
2017-03-06 | PHASE3 |
| NCT04215445 | UNKNOWN | Diabetic Retinopathy; Chronic Kidney Diseases; Diabetes Mellitus |
National University of Malaysia |
2019-12-01 | PHASE4 |
| NCT03254849 | COMPLETED | Type 2 Diabetes Mellitus |
Profil Institut für Stoffwechselforschung GmbH |
2017-12-08 | PHASE4 |
| NCT03485092 | COMPLETED | Heart Failure; Diabetes Mellitus |
NHS Greater Glasgow and Clyde |
2018-03-16 | PHASE4 |
| NCT03790787 | COMPLETED | Patients |
Hua Medicine Limited |
2019-04-18 | PHASE1 |
| NCT03030222 | COMPLETED | Heart Failure |
Saint Luke's Health System |
2017-07-05 | PHASE4 |
| NCT03173963 | WITHDRAWN | Diabetic Kidney Disease; Diabetes Mellitus Type 2 |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2017-05-27 | PHASE3 |
| NCT03713190 | COMPLETED | End Stage Renal Disease |
University of Pisa |
2018-09-10 | PHASE2 |
| NCT03485222 | COMPLETED | Cardiovascular Diseases |
Icahn School of Medicine at Mount Sinai |
2018-05-21 | PHASE4 |
| NCT03128528 | COMPLETED | Chronic Heart Failure |
University of Erlangen-Nürnberg Medical School |
2017-07-01 | PHASE2 |
| NCT02890745 | COMPLETED | Diabetes Mellitus, Type 2 |
Henrik Enghusen Poulsen |
2016-11 | PHASE2 |
| NCT03198585 | COMPLETED | Heart Failure With Reduced Ejection Fraction |
Morten Schou |
2017-06-29 | PHASE2 |
| NCT03510000 | COMPLETED | Type1diabetes |
Samuel Lunenfeld Research Institute, Mount Sinai Hospital |
2018-05-15 | |
| NCT03227484 | COMPLETED | PreDiabetes; Body Weight |
University Hospital Tuebingen |
2017-06-09 | PHASE2 |
| NCT03448406 | COMPLETED | Heart Failure |
Boehringer Ingelheim |
2018-03-20 | PHASE3 |
| NCT03448419 | COMPLETED | Heart Failure |
Boehringer Ingelheim |
2018-03-20 | PHASE3 |
| NCT03200860 | COMPLETED | Heart Failure Acute; Heart Failure，Congestive; Heart Failure; With Decompensation |
University Medical Center Groningen |
2017-12-18 | PHASE2 |
| NCT03271879 | UNKNOWN | Heart Failure; Diabetes Mellitus; Arrythmia |
Rambam Health Care Campus |
2018-02-15 | PHASE4 |
| NCT04061473 | COMPLETED | Diabetes After Total Pancreatectomy |
University Hospital, Gentofte, Copenhagen |
2019-04-02 | |
| NCT03208465 | COMPLETED | Diabetes Mellitus; Coronary Disease |
CHEOL WHAN LEE, M.D., Ph.D |
2017-08-07 | PHASE4 |
| NCT02798744 | COMPLETED | Diabetes Mellitus, Type 2 |
University of Leicester |
2016-12 | PHASE4 |
| NCT03078101 | COMPLETED | Diabetic Kidney Disease; Diabetes Mellitus, Type 2; Chronic Kidney Disease stage3; Chronic Kidney Disease stage4 |
Medical University of Vienna |
2017-04-15 | PHASE2 |
| NCT03504566 | WITHDRAWN | Diabetic Nephropathy Type 2 |
Steno Diabetes Center Copenhagen |
2017-11-15 | PHASE4 |
| NCT03351478 | COMPLETED | Type 2 Diabetes Mellitus |
Lexicon Pharmaceuticals |
2017-11-27 | PHASE3 |
| NCT03027960 | COMPLETED | Heart Failure; Type II; Diabetes |
Yale University |
2017-06-27 | PHASE1 |
| NCT03462069 | COMPLETED | Diabetes Mellitus |
Sanofi |
2018-03-12 | PHASE2 |
| NCT04143321 | COMPLETED | Diabetes Mellitus |
Isfahan University of Medical Sciences |
2018-09-10 | PHASE4 |
| NCT05132023 | COMPLETED | Healthy |
Genuine Research Center, Egypt |
2019-03-26 | PHASE1 |
| NCT03118336 | COMPLETED | Type 2 Diabetes |
Assistance Publique Hopitaux De Marseille |
2017-06-16 | PHASE3 |
| NCT03591991 | UNKNOWN | Reperfusion Injury, Myocardial |
Chinese PLA General Hospital |
2018-10-01 | |
| NCT03642184 | TERMINATED | New Onset Diabetes After Transplant; Kidney Transplant; Complications |
RenJi Hospital |
2018-07-14 | PHASE4 |
| NCT03132181 | COMPLETED | Diabetes Mellitus Type 2 (T2DM) |
RWTH Aachen University |
2017-04-24 | PHASE2 |
| NCT03766724 | COMPLETED | Type2 Diabetes |
Dong-A ST Co., Ltd. |
2018-11-22 | PHASE1 |
| NCT01001962 | UNKNOWN | Hypertension; Type II Diabetes |
Aristotle University Of Thessaloniki |
2016-01 | PHASE4 |
| NCT03639545 | UNKNOWN | Vascular Stiffness; Hypoglycemic Agents; Diabetes Complications; Diabetes Mellitus, Type 1 |
University Medical Centre Ljubljana |
2018-03-01 | PHASE4 |
| NCT03093103 | COMPLETED | Nephropathy |
Centre Hospitalier Universitaire Vaudois |
2017-03-16 | PHASE2 |
| NCT02874807 | COMPLETED | SIADH |
University Hospital, Basel, Switzerland |
2016-09-05 | PHASE2; PHASE3 |
| NCT03226457 | COMPLETED | Heart Failure; Type 2 Diabetes Mellitus |
University of Dundee |
2017-12-11 | PHASE4 |
| NCT02752113 | COMPLETED | Diabetes Mellitus Type 2 |
Institut für Pharmakologie und Präventive Medizin |
2016-04 | PHASE3 |
| NCT03629054 | COMPLETED | Healthy |
Boehringer Ingelheim |
2018-08-27 | PHASE1 |
| NCT04497792 | COMPLETED | Coronary Artery Disease; Diabetes Mellitus; Percutaneous Coronary Intervention |
Research Institute for Complex Problems of Cardiovascular Diseases, Russia |
2016-11 | PHASE4 |
| NCT02964715 | UNKNOWN | Type2 Diabetes; NAFLD |
University of Malaya |
2016-11 | PHASE4 |
| NCT03895229 | COMPLETED | Diabetes Mellitus; Pharmacokinetics; Pharmacodynamics |
Ain Shams University |
2018-10-01 | PHASE1 |
| NCT03458715 | UNKNOWN | Type2 Diabetes |
Mackay Memorial Hospital |
2017-09-21 | PHASE4 |
| NCT03200782 | COMPLETED | Postprandial Hypoglycemia; Bariatric Surgery; Late Dumping Syndrome |
University Hospital, Basel, Switzerland |
2017-05-30 | |
| NCT02998970 | UNKNOWN | Diabetes; Cardiovascular Disease |
Unity Health Toronto |
2017-01 | PHASE4 |
| NCT03565458 | UNKNOWN | Type 2 Diabetes Mellitus |
LG Chem |
2018-04-05 | PHASE1 |
| NCT02985242 | TERMINATED | Diabetes Mellitus, Type II |
Hannover Medical School |
2017-06-12 | PHASE4 |
| NCT02768220 | WITHDRAWN | SGLT-2 Inhibitors; Advanced Glycation End Products; Diabetes |
Northwell Health |
2017-12-01 | PHASE4 |
| NCT02637973 | COMPLETED | Type 2 Diabetes; Non-alcoholic Fatty Liver Disease |
The Deutsche Diabetes Forschungsgesellschaft e.V. |
2015-12 | PHASE4 |
| NCT03157414 | COMPLETED | Diabetes Mellitus; Renal Insufficiency; Safety Issues |
Oslo University Hospital |
2016-11-07 | PHASE4 |
| NCT03152552 | TERMINATED | Diabetes Mellitus and Heart Failure |
Novartis Pharmaceuticals |
2017-07-25 | PHASE2 |
| NCT03771781 | COMPLETED | Type 2 Diabetes |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2018-04-16 | |
| NCT03008551 | COMPLETED | Polycystic Ovary Syndrome |
Hull University Teaching Hospitals NHS Trust |
2017-08-18 | PHASE2; PHASE3 |
| NCT02918591 | UNKNOWN | Type 2 Diabetes |
Tel Aviv University |
2017-11 | |
| NCT03060980 | TERMINATED | Diabetes Mellitus, Type 2 |
Intarcia Therapeutics |
2017-03-03 | PHASE3 |
| NCT02833415 | COMPLETED | Obesity, Visceral |
University of Texas Southwestern Medical Center |
2016-03 | PHASE4 |
| NCT02632747 | COMPLETED | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Obesity |
Boehringer Ingelheim |
2016-05-10 | PHASE2 |
| NCT03259490 | COMPLETED | Healthy |
Boehringer Ingelheim |
2017-08-31 | PHASE1 |
| NCT03050229 | COMPLETED | Nocturnal Hypertension; T2DM (Type 2 Diabetes Mellitus) |
Jichi Medical University |
2017-01 | PHASE4 |
| NCT02728453 | TERMINATED | Diabetes Mellitus Type 2 |
Hannover Medical School |
2016-04-27 | PHASE4 |
| NCT02580591 | COMPLETED | Diabetes Mellitus, Type 1 |
Boehringer Ingelheim |
2015-12-22 | PHASE3 |
| NCT02686476 | COMPLETED | Non Alcoholic Fatty Liver Disease |
Medanta, The Medicity, India |
2016-03 | |
| NCT02863328 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-08-10 | PHASE3 |
| NCT02964572 | COMPLETED | Type2 Diabetes Mellitus |
Yonsei University |
2016-11 | |
| NCT03113110 | COMPLETED | Posttransplant Diabetes Mellitus |
Medical University of Vienna |
2017-01-15 | PHASE2 |
| NCT02589626 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2015-10-29 | PHASE4 |
| NCT04203914 | COMPLETED | Hypertension |
Yaounde Central Hospital |
2017-01-10 | PHASE4 |
| NCT02182830 | COMPLETED | Diabetes Mellitus, Type 2; Hypertension |
Boehringer Ingelheim |
2014-07-25 | PHASE3 |
| NCT02414958 | COMPLETED | Diabetes Mellitus, Type 1 |
Boehringer Ingelheim |
2015-06-30 | PHASE3 |
| NCT02589639 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2015-10-28 | PHASE4 |
| NCT03059056 | COMPLETED | Diabetes Mellitus |
British University In Egypt |
2017-02-02 | PHASE1 |
| NCT01984606 | WITHDRAWN | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2015-01 | PHASE3 |
| NCT02489968 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2015-05-12 | PHASE3 |
| NCT02815644 | COMPLETED | Healthy |
Boehringer Ingelheim |
2016-07-15 | PHASE1 |
| NCT02821910 | COMPLETED | Healthy |
Boehringer Ingelheim |
2016-07-20 | PHASE1 |
| NCT02702011 | COMPLETED | Diabetes Mellitus, Type 1 |
Boehringer Ingelheim |
2016-03-20 | PHASE2 |
| NCT02854748 | UNKNOWN | Diabetes Mellitus, Type II |
Chong Kun Dang Pharmaceutical |
2016-08 | PHASE1 |
| NCT02453555 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2015-05-14 | PHASE3 |
| NCT02792400 | COMPLETED | Type 2 Diabetes |
University Hospital, Gentofte, Copenhagen |
2016-05 | |
| NCT02758171 | COMPLETED | Healthy |
Boehringer Ingelheim |
2016-05-17 | PHASE1 |
| NCT02729766 | COMPLETED | Inappropriate ADH Syndrome |
University Hospital, Basel, Switzerland |
2016-03 | PHASE2; PHASE3 |
| NCT02121483 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2014-06 | PHASE1 |
| NCT02401880 | COMPLETED | Type 2 Diabetes Mellitus |
Profil Institut für Stoffwechselforschung GmbH |
2015-05 | PHASE4 |
| NCT02471963 | COMPLETED | Diabetes Mellitus Type 2 |
University of Erlangen-Nürnberg Medical School |
2014-12 | PHASE3 |
| NCT01867307 | COMPLETED | Diabetes Mellitus, Type 2; Healthy |
Boehringer Ingelheim |
2013-06 | PHASE2 |
| NCT02577315 | COMPLETED | Healthy |
Boehringer Ingelheim |
2015-09 | PHASE1 |
| NCT01734785 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2013-02-08 | PHASE3 |
| NCT01778049 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2013-01 | PHASE3 |
| NCT02266472 | COMPLETED | Healthy |
Boehringer Ingelheim |
2014-11 | PHASE1 |
| NCT01719003 | COMPLETED | Diabetes Mellitus, Type 2; Hyperglycemia |
Boehringer Ingelheim |
2012-10 | PHASE3 |
| NCT02230995 | COMPLETED | Healthy |
Boehringer Ingelheim |
2014-09 | PHASE1 |
| NCT02102932 | COMPLETED | Healthy |
Boehringer Ingelheim |
2014-05 | PHASE1 |
| NCT02106923 | COMPLETED | Healthy |
Boehringer Ingelheim |
2014-04 | PHASE1 |
| NCT01969747 | COMPLETED | Diabetes Mellitus, Type 1 |
Boehringer Ingelheim |
2013-11 | PHASE2 |
| NCT02028767 | COMPLETED | Healthy |
Boehringer Ingelheim |
2014-01 | PHASE1 |
| NCT01649297 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2012-10 | PHASE2 |
| NCT01975220 | COMPLETED | Healthy |
Boehringer Ingelheim |
2013-10 | PHASE1 |
| NCT01947855 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2013-09 | PHASE3 |
| NCT01844531 | COMPLETED | Healthy |
Boehringer Ingelheim |
2013-04 | PHASE1 |
| NCT01248364 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2010-11 | PHASE2 |
| NCT01811953 | COMPLETED | Healthy |
Boehringer Ingelheim |
2013-03 | PHASE1 |
| NCT01581658 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2012-04-01 | PHASE1 |
| NCT01672788 | COMPLETED | Healthy |
Boehringer Ingelheim |
2012-08 | PHASE1 |
| NCT01634100 | COMPLETED | Healthy |
Boehringer Ingelheim |
2012-06 | PHASE1 |
| NCT01451775 | COMPLETED | Healthy |
Boehringer Ingelheim |
2011-10 | PHASE1 |
| NCT02782624 | COMPLETED | Healthy |
Boehringer Ingelheim |
2009-09 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-04-16)
Check the
BI-10773 (Empagliflozin)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- BI-10773 (Empagliflozin) Mechanism of Action: SGLT2 Inhibition in Cardiomyocytes Research
- BI-10773 (Empagliflozin): Selectivity & Specificity
- BI-10773 (Empagliflozin) Working Concentration | Cell Culture | Treatment
- BI-10773 (Empagliflozin) Solubility in DMSO
- BI-10773 (Empagliflozin) Stock Solution
- BI-10773 (Empagliflozin) Storage
- BI-10773 (Empagliflozin) Stability
- BI-10773 (Empagliflozin) Combination Database
- BI-10773 (Empagliflozin) Molecular Weight
- BI-10773 (Empagliflozin) SMILES
- BI-10773 (Empagliflozin) CAS Number
- BI-10773 (Empagliflozin) Chemical Structure (2D and 3D)
- BI-10773 (Empagliflozin) IC50 for Cell-based and Cell-free Assays
- BI-10773 (Empagliflozin) Sigma (SML4200)? Try a better option.
- BI-10773 (Empagliflozin) MedChemExpress (HY-15409)? Try a better option.
- BI-10773 (Empagliflozin) Cayman (17375)? Try a better option.
- BI-10773 (Empagliflozin) APExBIO (A4601)? Try a better option.
- BI-10773 (Empagliflozin) Axonmedchem (Axon 3367)? Try a better option.
- BI-10773 (Empagliflozin) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.